Notably, second-generation FLT3 inhibitors, such as quizartinib, a potent type II inhibitor that selectively targets the FLT3-ITD mutation [12], and gilteritinib, a type I inhibitor that targets FLT3-ITD and TKD mutations [13], have been demonstrated to improve OS and increase remission rates in patients with relapsed or refractory (R/R) FLT3-mutated AML, compared with conventional chemotherapy [14–18]. Here, FLT3 is linked to acute myeloid leukemia.